Misplaced Pages

Noradrenergic and specific serotonergic antidepressant

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Bwiki (talk | contribs) at 19:12, 8 April 2006 (sp: side-effects --> side effects). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 19:12, 8 April 2006 by Bwiki (talk | contribs) (sp: side-effects --> side effects)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to act by noradrenergic autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission.

Examples of NaSSAs include:

  • Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®)

NaSSAs are said to have fewer side effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with NaSSAs.

See also

External links

Stub icon

This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it.

Categories: